Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAloha Care step therapy Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentAloha CarePolicy N/A

    2026 AlohaCare Advantage (HMO D-SNP) Drugs with Step Therapy Requirements

    Customize your policy alerts

    Sign up for all Aloha Care policy alerts

    Know when Aloha Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists drugs subject to step therapy requirements for AlohaCare Advantage (HMO D-SNP) members and the required prior trials before coverage; applies to prescribers requesting coverage under this plan.

    Policy Summary
    PayerAloha Care
    PolicyDrugs with Step Therapy Requirements (AlohaCare Advantage HMO D-SNP) — 2026
    Policy CodePolicy N/A
    Change TypeAdministrative review — no material changes
    Effective DateJun 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionDocument a prior trial of the specified alternative therapy before requesting coverage (e.g., trial of generic alternatives or listed prior agents as required by each drug’s criteria).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8+distinct product or therapy sections listed in this part
    Diclofenac, Invega, Rytarysample products affected
    1–2typical required number of prior trials

    Coverage Criteria by Drug / Group

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Actinic keratosis — Diclofenac Sodium GEL 3%

    Diclofenac Sodium GEL 3% is covered when ALL of the following are met:

    Actinic keratosis prior therapy: Trial of either topical fluorouracil or topical imiquimod1 trial

    From document chunk 3

    Antidepressants — specified products (Emsam, Exxua, Fetzima, etc.)

    Emsam, Exxua, Exxua Titration Pack, Fetzima and Fetzima Titration Pack are covered when ONE of the following is met:

    Two-generic trial: Trial of two generics from: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride2 trials

    Approve for continuation of prior therapy

    Atypical antipsychotics — Fanapt group

    Fanapt and related products are covered when ONE of the following are met:

    Two-generic atypical antipsychotic trial: Trial of two of: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone2 trials

    Approve for continuation of prior therapy

    Invega Hafyera therapy

    Invega Hafyera is covered when ALL of the following are met for new starts:

    Prior LAI trial: Trial of Invega Sustenna or Invega Trinza1 trial

    Step applies to new starts only. Approve for continuation of prior therapy.

    Relistor

    Relistor is covered when ALL of the following are met:

    Prior laxative trial: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose1 trial

    From document chunk 15

    Rytary

    Rytary is covered when ALL of the following are met:

    Prior carbidopa/levodopa trial: Trial of one generic carbidopa/levodopa containing formulation1 trial

    From document chunk 18

    Carbidopa/Levodopa - Step Requirement example

    Example listed step requirement

    Carbidopa/Levodopa trial: Trial of one generic carbidopa/levodopa containing formulation is required1 trial

    From criteria index (document chunk 18)

    Zonisade - Initial Therapy step therapy rule

    Zonisade (Zonisade suspension) step therapy rule

    Zonisade trial: Trial of a generic zonisamide capsule required for new starts1 trial

    Continuation of prior therapy is approved

    For Invega Hafyera, the step therapy requirement applies only to new starts. Coverage for a new start requires documentation of a trial of Invega Sustenna or Invega Trinza. Members already receiving Invega Hafyera as an ongoing therapy may be approved for continuation without repeating the step requirement; document prior therapy status when requesting continuation.

    The listed step therapy for products in this entry applies only to new starts. Approval for a new start requires evidence of a trial of a generic zonisamide capsule. Members already stabilized on the product may be approved for continuation of prior therapy without meeting the new-start step requirement; include documentation of prior therapy when requesting continuation.

    Actions, Documentation, and Prior Authorization Requirements

    Prior Authorization

    Actinic keratosis — prior topical therapy required

    Diclofenac Sodium GEL 3% requires documented evidence of a prior trial of either topical fluorouracil or topical imiquimod before coverage is approved.

    • Required prior trial: topical fluorouracil OR topical imiquimod
    Prior Authorization

    Antidepressants — two generic trials required

    Emsam, Exxua (and Exxua Titration Pack), Fetzima (and Fetzima Titration Pack) require trials of two generic antidepressants from the specified formulary list prior to approval; continuation is allowed for members already on therapy.

    • Required trials: two generics from bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride
    • Continuation of prior therapy may be approved without repeating step
    Prior Authorization

    Atypical antipsychotics — two generic trials required

    Fanapt and related products (Fanapt titration packs, Lybalvi, Secuado) require trials of two generic formulary atypical antipsychotics from the listed agents prior to approval; continuation of prior therapy is permitted.

    • Required trials: two of asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
    • Continuation of prior therapy may be approved without repeating step
    Prior Authorization

    Invega Hafyera — prior LAI trial for new starts

    For new starts of Invega Hafyera, a prior trial of Invega Sustenna or Invega Trinza is required; members already on Invega Hafyera may be continued without meeting the new-start step.

    • Required prior LAI trial for new starts: Invega Sustenna OR Invega Trinza
    • Step applies to new starts only; continuation of prior therapy approved
    Prior Authorization

    Relistor — prior laxative trial required

    Relistor requires documentation of a prior trial of an acceptable laxative before approval.

    • Acceptable laxatives: lubiprostone, Constulose, Enulose, Generlac, or lactulose
    • One trial of an acceptable laxative is required per criteria
    Prior Authorization

    Rytary — prior carbidopa/levodopa trial required

    Rytary requires a prior trial of one generic carbidopa/levodopa–containing formulation before coverage is approved.

    • Required trial: one generic carbidopa/levodopa containing formulation
    Prior Authorization

    Zonisade suspension — prior authorization and trial

    Zonisade (Zonisade suspension) requires prior authorization for new starts with documentation of a trial of a generic zonisamide capsule; members already receiving zonisamide may be continued.

    • Required prior trial for new starts: generic zonisamide capsule
    • Continuation allowed for members already on therapy
    Prior Authorization

    Carbidopa/levodopa — prior authorization requirement

    Carbidopa/levodopa products listed in the index require documentation of a prior trial of one generic carbidopa/levodopa formulation as a condition of coverage.

    • Required trial: one generic carbidopa/levodopa containing formulation
    Step Therapy

    Actinic keratosis — step therapy requirement

    Diclofenac Sodium GEL 3% must be preceded by a trial of either topical fluorouracil or topical imiquimod (step 1) before approval is granted.

    • Step 1 requirement: trial of topical fluorouracil OR topical imiquimod
    Step Therapy

    Antidepressant group — step therapy requirement

    The antidepressant group (Emsam, Exxua, Fetzima and their titration packs) requires trials of two generic formulary antidepressants (from the specified list) as the step requirement; continuation of prior therapy is allowed.

    • Step 1 requirement: two generic trials from the listed antidepressant agents
    • Continuation of prior therapy may be approved
    Step Therapy

    Atypical antipsychotics — step therapy requirement

    Fanapt, Lybalvi, Secuado and related products require trials of two generic formulary atypical antipsychotics (step 1) prior to approval; continuation of prior therapy is allowed.

    • Step 1 requirement: two trials from asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
    • Continuation of prior therapy may be approved
    Step Therapy

    Invega Hafyera — step therapy for new starts

    For new starts of Invega Hafyera, the step requirement is a trial of Invega Sustenna or Invega Trinza (step 1); members already on therapy may be continued without meeting this step.

    • Step 1 requirement for new starts: Invega Sustenna OR Invega Trinza
    • Step applies to new starts only; continuation approved
    Step Therapy

    Relistor — step therapy requirement

    Relistor’s step requires a prior trial of one of the specified laxatives before approval (lubiprostone, Constulose, Enulose, Generlac, or lactulose).

    • Step 1 requirement: trial of lubiprostone, Constulose, Enulose, Generlac, OR lactulose
    Step Therapy

    Rytary — step therapy requirement

    Rytary’s step therapy requires a trial of one generic carbidopa/levodopa formulation (step 1) prior to approval.

    • Step 1 requirement: trial of one generic carbidopa/levodopa containing formulation
    Note

    Step therapy example — carbidopa/levodopa

    Example step definition: step 1 corresponds to a trial of one generic carbidopa/levodopa–containing formulation (used as the example step entry in the criteria index).

    • Example: Step 1 = trial of one generic carbidopa/levodopa formulation
    Step Therapy

    Zonisade — step therapy for new starts

    Zonisade step therapy requires a trial of a generic zonisamide capsule for new starts (step 1); continuation is approved for members already on zonisamide without meeting the step.

    • Step 1 requirement (new starts): trial of generic zonisamide capsule
    • Step applies to new starts only; continuation of prior therapy approved
    Documentation Required

    Continuation of prior therapy — document status

    When continuation of prior therapy is applicable, approve continuation and document the member’s prior therapy status in the request.

    • Document that member is already receiving the product to allow continuation approval
    Documentation Required

    Zonisade — required documentation for new starts

    For Zonisa­de new starts, documentation must demonstrate a trial of a generic zonisamide capsule; include prior therapy history to support continuation if applicable.

    • Provide records showing trial of generic zonisamide capsule for new starts
    • Include prior medication history if requesting continuation
    Documentation Required

    Carbidopa/levodopa — documentation requirement

    For carbidopa/levodopa step requirements, document a prior trial of one generic carbidopa/levodopa–containing formulation as specified in the criteria index.

    • Record the product name and dates of the generic carbidopa/levodopa trial
    Denial Risk

    Actinic keratosis — denial risk for missing prior trial

    Coverage for Diclofenac Sodium GEL 3% may be denied if there is no documentation of a prior trial of either topical fluorouracil or topical imiquimod.

    • Lack of the required prior topical trial can result in denial
    Denial Risk

    Antidepressants — denial risk for missing prior trials

    Coverage for the listed antidepressants may be denied if documentation does not show trials of two required generic antidepressants from the formulary list.

    • Absence of two documented generic trials can lead to denial
    Denial Risk

    Atypical antipsychotics — denial risk for missing prior trials

    Coverage for Fanapt and related atypical antipsychotic products may be denied if two trials of generic formulary atypical antipsychotics are not documented.

    • Failure to document two required generic atypical antipsychotic trials may result in denial
    Denial Risk

    Invega Hafyera — denial risk for missing LAI trial

    For new starts of Invega Hafyera, absence of a documented trial of Invega Sustenna or Invega Trinza may lead to denial.

    • New starts without documentation of the required LAI trial risk denial
    Denial Risk

    Relistor — denial risk for missing prior laxative trial

    Coverage for Relistor may be denied if there is no documentation of a trial of an acceptable laxative (lubiprostone, Constulose, Enulose, Generlac, or lactulose).

    • Absence of a documented laxative trial can result in denial
    Denial Risk

    Rytary — denial risk for missing prior trial

    Coverage for Rytary may be denied if there is no documentation of a trial of one generic carbidopa/levodopa–containing formulation.

    • Missing documentation of the required generic carbidopa/levodopa trial may lead to denial
    Denial Risk

    Zonisade — denial risk for missing step on new starts

    For Zonisade new starts, failure to document a trial of a generic zonisamide capsule may trigger denial; the step applies only to new starts.

    • Step applies to new starts only; document the generic trial to avoid denial
    Denial Risk

    Carbidopa/levodopa — denial risk for missing step

    Carbidopa/levodopa entries require a documented trial of one generic carbidopa/levodopa formulation per the criteria; absence may result in denial.

    • Document the generic formulation trial to meet step requirement

    Initial Therapy / New Start Requirements

    Invega Hafyera initial therapy

    Specific initial therapy rule for Invega Hafyera

    New start requirement: Trial of Invega Sustenna or Invega Trinza required for new starts1 trial

    From document chunk 12

    Initial therapy requirements — Zonisade and carbidopa/levodopa examples

    Initial therapy step requirements

    Zonisade initial: Trial of generic zonisamide capsule required for new starts1 trial

    From ZONISADE SUSPENSION - SCORE (chunk 21)

    Carbidopa/Levodopa initial: Trial of one generic carbidopa/levodopa containing formulation1 trial

    From criteria index (chunk 18)

    Continuation of Prior Therapy

    Continuation of prior therapy — allowed for specified products

    Continuation of prior therapy is allowed for specified products.

    Continuation allowed: Approve for continuation of prior therapy when member already on product

    Referenced for antidepressants, atypical antipsychotics, and Invega Hafyera

    Zonisade continuation — continuation rules for patients already on therapy

    Continuation rules for patients already on therapy

    Continuation approval: Approve continuation of prior zonisamide therapy without requiring the generic capsule trial

    Step applies to new starts only

    Step Therapy Table (Required Prior Trials)

    DrugRequired prior therapy (step 1)Notes
    {"text":"Diclofenac Sodium GEL 3%","status":""}~{"text":"Trial of either topical fluorouracil or topical imiquimod","status":""}~{"text":"Step = 1 trial","status":""}
    Drug group / productsRequired prior therapy (step 1)Notes
    {"text":"Emsam; Exxua; Exxua Titration Pack; Fetzima; Fetzima Titration Pack","status":""}~{"text":"Trial of two generics from: bupropion; mirtazapine; citalopram; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine hydrochloride","status":""}~{"text":"Approve for continuation of prior therapy","status":""}
    Drug group / productsRequired prior therapy (step 1)Notes
    {"text":"Fanapt and related products (Fanapt Titration Pack C; Lybalvi; Secuado)","status":""}~{"text":"Trial of two of the following generic atypical antipsychotics: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone","status":""}~{"text":"Approve for continuation of prior therapy","status":""}
    DrugRequired prior therapy (step 1)Notes / applicability
    {"text":"Invega Hafyera","status":""}~{"text":"Trial of Invega Sustenna or Invega Trinza","status":""}~{"text":"Step applies to new starts only; approve continuation of prior therapy","status":""}
    DrugRequired prior therapy (step 1)Notes
    {"text":"Relistor","status":""}~{"text":"Trial of lubiprostone; Constulose; Enulose; Generlac; or lactulose","status":""}~{"text":"Step = 1 trial","status":""}
    DrugRequired prior therapy (step 1)Notes
    {"text":"Rytary","status":""}~{"text":"Trial of one generic carbidopa/levodopa containing formulation","status":""}~{"text":"Step = 1 trial","status":""}
    DrugRequired prior therapy (step 1)Notes
    {"text":"Zonisade (Zonisade suspension)","status":""}~{"text":"Trial of a generic zonisamide capsule","status":""}~{"text":"Step applies to new starts only; approve continuation for members already on therapy","status":""}
    Index / exampleRequired prior therapy (step 1)Notes
    {"text":"Carbidopa/Levodopa (example entry)","status":""}~{"text":"Trial of one generic carbidopa/levodopa containing formulation","status":""}~{"text":"Step = 1 trial (per criteria index)","status":""}

    Background and Scope

    This section summarizes drug-specific step therapy rules used by the plan. Each entry defines the required prior trial(s) for a new start of a specified product (for example, a trial of Invega Sustenna or Invega Trinza before Invega Hafyera, or a trial of a generic zonisamide capsule before Zonisade). Where noted, these step requirements apply only to new starts; continuation of prior therapy is authorized for members already receiving the product, provided prior therapy is documented.

    Definitions

    Step therapy — definition/key-value
    DefinitionStep therapy: A requirement that a member try specified alternative medication(s) first before coverage is allowed for the requested drug.
    ApplicabilityApplies to new starts for listed products; continuation of prior therapy is approved when member already on product.
    Typical requirementMost entries require trial of 1 alternative; some classes (e.g., certain antidepressants and atypical antipsychotics) require trials of 2 generics from a specified list.
    Provider action (most actionable)Document and verify trial(s) of the required alternative(s) (e.g., trial of one generic carbidopa/levodopa before Rytary; trial of generic zonisamide capsule for new starts of Zonisade; trial of Invega Sustenna or Invega Trinza for new starts of Invega Hafyera).
    Denial riskLack of documented required prior trial(s) may result in denial of coverage for the requested product.
    Policy Summary
    PayerAloha Care
    PolicyDrugs with Step Therapy Requirements (AlohaCare Advantage HMO D-SNP) — 2026
    Policy CodePolicy N/A
    Change TypeAdministrative review — no material changes
    Effective DateJun 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionDocument a prior trial of the specified alternative therapy before requesting coverage (e.g., trial of generic alternatives or listed prior agents as required by each drug’s criteria).
    SourceLink
    On This Page
    Coverage Criteria by Drug / GroupActions, Documentation, and Prior Authorization RequirementsInitial Therapy / New Start RequirementsContinuation of Prior TherapyStep Therapy Table (Required Prior Trials)Background and ScopeDefinitions